Marketing Authorisation Holder
The current MA holder for Baricitinib is Eli Lily. Sites should use local stock of Baricitinib
Dosing regime
Baricitinib will be administered orally (or crushed for nasogastric tube delivery) at a dose of 4 mg/day given daily for up to 14 days or until discharge from critical care units, whichever occurred first.
Dose changes
If the patient has a baseline eGFR of 30 to less than 60 mL/min/1·73 m2, then the baricitinib dosing will be at 2mg/day given daily orally (or crushed for nasogastric tube delivery) for up to 14 days or until discharge from critical care units, whichever occurred first.
If after randomization eGFR decreases to less than 60 mL/min/1.73 m2 but more than 30 mL/min/1.73 m2, patients will receive 2mg/day given daily orally (or crushed for nasogastric tube delivery) until eGFR returns to eGFR ≥60 mL/min/1.73 m2, for up to 14 days or until discharge from critical care units, whichever occurred first.
Baricitinib is not recommended for use in patients with estimated GFR of <30 mL/min/1.73 m2.
Date entered TRAITS
July 2023